Kyverna Therapeutics’ (KYTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kyverna Therapeutics (NASDAQ:KYTX) in a research note published on Thursday,Benzinga reports. They currently have a $20.00 price objective on the stock.

Several other analysts have also weighed in on KYTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th. Wall Street Zen lowered shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.67.

Kyverna Therapeutics Stock Performance

Shares of NASDAQ KYTX opened at $9.06 on Thursday. The firm has a market capitalization of $548.40 million, a price-to-earnings ratio of -2.48 and a beta of 2.62. Kyverna Therapeutics has a one year low of $1.92 and a one year high of $13.67. The business has a fifty day simple moving average of $8.65 and a 200 day simple moving average of $8.15. The company has a current ratio of 7.75, a quick ratio of 7.75 and a debt-to-equity ratio of 0.11.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.80) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.80). Sell-side analysts expect that Kyverna Therapeutics will post -3.18 EPS for the current year.

Institutional Trading of Kyverna Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wesbanco Bank Inc. bought a new position in shares of Kyverna Therapeutics in the first quarter valued at about $952,000. Grey Ledge Advisors LLC bought a new stake in Kyverna Therapeutics during the 1st quarter worth about $86,000. Banque Cantonale Vaudoise bought a new stake in Kyverna Therapeutics during the 1st quarter worth about $263,000. Empowered Funds LLC acquired a new stake in Kyverna Therapeutics in the 4th quarter valued at about $169,000. Finally, Quadrature Capital Ltd acquired a new stake in Kyverna Therapeutics in the 4th quarter valued at about $539,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.